Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0699790 (colon cancer)
 28,837 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Stereotactic body radiation therapy (SBRT) delivers large doses of radiation with great accuracy, but is known to have deleterious effects on the vascular compartment of irradiated tissues. Combining SBRT with targeted anti-angiogenesis agents, while able to increase therapeutic efficacy, may unexpectedly precipitate vascular-based toxicities. In this report, we describe a patient with colon cancer who developed transverse myelopathy from regorafenib 2 years after receiving SBRT for three metastatic liver lesions. Regorafenib (Stivarga), formerly BAY 73-4506, (Bayer HealthCare Pharmaceuticals, Montville, NJ) is a multiple receptor tyrosine kinase inhibitor with anti-angiogenic effects used in metastatic colon cancer. Its most common side effects are fatigue, diarrhea and hypertension. However, severe neurologic toxicity has not been previously recognized. Here, we illustrate a case in which the patient developed hyperalgesia and radicular pain 2 weeks after starting regorafenib. Several studies report an increased neurological toxicity when angiogenesis inhibitors are given after radiation therapy, and we postulate that the angioinhibitory effects of regorafenib accelerated subclinical microvascular injury from SBRT. This unexpected toxicity may be clinically relevant when giving targeted angiogenesis inhibitors after SBRT.
...
PMID:Regorafenib-induced transverse myelopathy after stereotactic body radiation therapy. 2543 37

We report and analyze a rare entity of intramedullary spinal cord tumor, which is metastatic from colon cancer with a very poor prognosis. The reported 19 cases including our case in the literature are analyzed. Comparison of outcomes between surgery, radiotherapy and non-treatment groups are evaluated. Life distribution is profiled. Median overall survival is 75 days. The 90 days and 150 days survival rate are 42.9% and 21.4%, respectively. There were no differences between conservative treatment (non-treatment or radiotherapy) and aggressive intervention (surgery or surgery plus radiotherapy) in mortality and the trend of survival probability. The prognosis of metastatic intramedullary spinal cord tumor is poor. Surgery may only be considered in selected patients with good control of primary cancer and without evidence of lung metastases and leptomeningeal carcinomatosis.
Spinal Cord Ser Cases 2016
PMID:Intramedullary spinal cord metastasis from colon cancer: analysis of 19 reported cases. 3126 10